BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 1-127, without prejudice.

1.-127. (Canceled)

Add new claims 128-203, as follows:

128. (New) A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:11, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount results in an effective neutralizing titer of the antibody.

129. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:254, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.

130. (New) The antibody of claim 128 further comprising a VH domain having an amino acid sequence of SEQ ID NO:254.

131. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:10, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.

132. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.

133. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.

134. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:39, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.

135. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5, wherein the antibody immunospecifically binds to a RSV antigen and the antibody is not palivizumab, and wherein the effective amount of the antibody results in an effective neutralizing titer of the antibody.

136. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6, wherein the antibody immunospecifically binds to a RSV antigen and the antibody is not palivizumab, and wherein the effective amount of the antibody results in an effective neutralizing titer of the antibody.

137. (New) The method of claim 131, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

138. (New) The method of claim 131, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

139. (New) The method of claim 131, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

140. (New) The method of claim 132, wherein the antibody further comprises a VL CDR 1 having an amino acid sequence of SEQ ID NO:39.

141. (New) The method of claim 132, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

142. (New) The method of claim 132, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

143. (New) The method of claim 133, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

144. (New) The method of claim 133, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

145. (New) The method of claim 133, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

146. (New) The method of claim 131, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

147. (New) The method of claim 131, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

148. (New) The method of claim 132, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

149. (New) The method of claim 146, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

150. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

151. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

152. (New) The method of claim 146, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

153. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

154. (New) The method of claim 147, wherein the antibody further comprises a VL

CDR2 having an amino acid sequence of SEQ ID NO:5.

155. (New) The method of claim 147, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

156. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

157. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

158. (New) The method of claim 148, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

159. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

160. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

161. (New) The method of claim 149, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

162. (New) The method of claim 134, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

163. (New) The method of claim 134, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:5.

164. (New) The method of claim 135, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

165. (New) The method of claim 162, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

166. (New) The method of claim 162, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

167. (New) The method of claim 162, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

168. (New) The method of claim 162, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

169. (New) The method of claim 163, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

170. (New) The method of claim 163, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

171. (New) The method of claim 163, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

172. (New) The method of claim 164, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

173. (New) The method of claim 164, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

174. (New) The method of claim 164, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

175. (New) The method of claim 165, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

176. (New) The method of claim 165, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

177. (New) The method of claim 165, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

178. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

179. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

180. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino

acid sequence of SEQ ID NO:6.

181. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

182. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

183. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

184. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

185. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

186. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

187. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

188. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

189. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid

sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

190. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

191. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

192. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

193. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

194. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective amount is 15 mg/kg or less, 10 mg/kg or less, 5 mg/kg or less or 3 mg/kg or less or 1.5 mg/kg or less.

195. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective neutralizing titer is at least 1 μg/ml, at least 2 μg/ml , at least 4 μg/ml, at least 6 μg/ml, at least 30 μg/ml, 35 μg/ml, at least 40 μg/ml, at least 50 μg/ml, at least 75 μg/ml, at least 100 μg/ml, at least 150 μg/ml or at least 200 μg/ml.

196. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective neutralizing titer is maintained for at least 20 days, at least 25 days or at least 30 days after administration of the dose.

197. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered by a nebulizer or inhaler.

198. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered intramusclarly, intravenously or subcutaneously.

199. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is a monoclonal antibody, a human antibody, a humanized antibody, a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.

200. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered 1, 2, 3, 4 or 5 times during the RSV season.

201. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the mammal is a human subject.

202. (New) The method of claim 201, wherein the human subject is a human infant, a human infant born prematurely or at risk of hospitalization for a RSV infection, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

203. (New) The method of any one of claims 128, 129, 130 or 131-134 further comprising administering to the mammal hormonal therapy, immunotherapy or an anti-inflammatory agent.